FTC sues insulin middlemen, saying they pocket billions while patients face high costsThe FTC is targeting pharmacy benefit managers to address high insulin costs, which have shot up by 600% over two decades, impacting diabetic patients.
FTC goes after drug middlemen for allegedly jacking up insulin pricesThe FTC is suing three PBMs for allegedly inflating insulin prices, impacting many Americans reliant on the drug.
The FTC Is Suing PBMs Over Insulin Prices. Will It Be Successful? - MedCity NewsThe FTC is suing major pharmacy benefit managers for unfair practices affecting insulin prices and patient access.
Healthcare Leaders Support FTC's Second Report on PBMs, While PBMs Criticize Findings - MedCity NewsFTC report reveals significant price hikes by PBMs on critical medications, calling for investigations into practices inflating drug costs and harming healthcare accessibility.
FTC sues insulin middlemen, saying they pocket billions while patients face high costsThe FTC is targeting pharmacy benefit managers to address high insulin costs, which have shot up by 600% over two decades, impacting diabetic patients.
FTC goes after drug middlemen for allegedly jacking up insulin pricesThe FTC is suing three PBMs for allegedly inflating insulin prices, impacting many Americans reliant on the drug.
The FTC Is Suing PBMs Over Insulin Prices. Will It Be Successful? - MedCity NewsThe FTC is suing major pharmacy benefit managers for unfair practices affecting insulin prices and patient access.
Healthcare Leaders Support FTC's Second Report on PBMs, While PBMs Criticize Findings - MedCity NewsFTC report reveals significant price hikes by PBMs on critical medications, calling for investigations into practices inflating drug costs and harming healthcare accessibility.